Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Felip, E.; Cho, B.C.; Gutiérrez, V.; Alip, A.; Besse, B.; Lu, S.; Spira, A.I.; Girard, N.; Califano, R.; Gadgeel, S.M.; Yang, J.C.-H.; Yamamoto, S.; Azuma, K.; Kim, Y.J.; Lee, K.-H.; Danchaivijitr, P.; Ferreira, C.G.; Cheng, Y.; Sendur, M.A.N.; Chang, G.-C.; Wang, C.-C.; Prabhash, K.; Shinno, Y.; Stroyakovskiy, D.; Paz-Ares, L.; Rodriguez-Cid, J.R.; Martin, C.; Campelo, M.R.G.; Hayashi, H.; Nguyen, D.; Tomasini, P.; Gottfried, M.; Dooms, C.; Passaro, A.; Schuler, M.; Gelatti, A.C.Z.; Owen, S.; Perdrizet, K.; Ou, S.-H.I.; Curtin, J.C.; Zhang, J.; Gormley, M.; Sun, T.; Panchal, A.; Ennis, M.; Fennema, E.; Daksh, M.; Sethi, S.; Bauml, J.M.; Lee, S.-H.

doi:10.1016/j.annonc.2024.05.541

Annals of Oncology

2024

DOI: 10.1016/j.annonc.2024.05.541

|View full text |Cite

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

E. Felip,

B.C. Cho,

V. Gutiérrez

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 10 publications

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review

Podder,

Ranjan,

Gowda

et al. 2024

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review

Podder,

Ranjan,

Gowda

et al. 2024

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?

Nishimura,

Fujimoto

2024

Annals of Oncology

View full text Add to dashboard Cite

Reply to the Letter to the Editor regarding ‘PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?’ by T. Nishimura and H. Fujimoto

Felip,

Cho,

Nguyen

et al. 2024

Annals of Oncology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Cited by 10 publications

References 37 publications

Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review

Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review

PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?

Reply to the Letter to the Editor regarding ‘PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?’ by T. Nishimura and H. Fujimoto

Contact Info

Product

Resources

About